Clinical-epidemiological description of patients with inflammatory bowel disease in a fourth level clinic in Cali
DOI:
https://doi.org/10.22516/25007440.409Keywords:
ulcerative colitis, Crohn’s disease, Inflammatory bowel diseasesAbstract
Objectives: In Latin America, inflammatory bowel disease (IBD) is rare, and information about it is limited. This article describes characteristics of IBD patients in a gastroenterology unit at a high-level clinic in Cali, Colombia.
Materials and methods: This is a descriptive study of patients diagnosed with Crohn’s disease (CD) or ulcerative colitis (UC) at the Clínica Fundación Valle de Lili between January 2011 and December 2015. Statistical analysis was performed with SPSS version 19. Medians and interquartile ranges were calculated for numerical variables. Frequencies were calculated for qualitative variables.
Results: The 416 participants included 115 with CD and 301 with UC. Of the total cases, 41% were classified as mild, 23.5% as moderate and 35.3% as severe. Surgery was performed in 24 patients (9.0%) with UC and 53 (46.1%) with CD. CD was most frequently managed with biologicals (32.2%), followed by immunomodulators (27.8%), steroids (20%) and 5-ASA (11.3%). The most frequent treatment for UC was 5-ASA (84.8%), but 32.19% received steroids, 24.6% received azathioprine and 15.9% received biologicals.
Conclusions: Early diagnosis remains a challenge. The severity of UC but not CD in the patients studied was less than that reported elsewhere in the world. The difference could be related to diagnostic delay. The use of biologicals was close to that reported in the first world. It is difficult to determine if lower surgery rates are due to better clinical response or to difficult access to these interventions.
Downloads
References
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG.. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54.e42.
https://doi.org/10.1053/j.gastro.2011.10.001
Figueroa CC, Quera PR, Valenzuela EJ, Jensen BC. Enfermedades inflamatorias intestinales: Experiencia de dos centros chilenos. Rev Med Chil. 2005;133(11):1295-304.
https://doi.org/10.4067/S0034-98872005001100004
Kamm MA. Rapid changes in epidemiology of inflammatory bowel disease. Lancet. 2017;390(10114):2741-2. https://doi.org/10.1016/S0140-6736(17)32669-7
Lega-Siccar J, Lega LI. Colitis ulcerativa y enfermedad de Crohn del colon. Acta Médica Colomb. 1991;16(3):140-52.
Juliao-Baños F, Ruiz-Vélez MH, Flórez-Arango JF, Donado-Gómez JH, Marín-Zuluaga JI, Monsalve-Arango C, Jiménez-Gómez CA, Agudelo-Zapata Y, Velayos FS. Fenotipo e historia natural de la enfermedad inflamatoria intestinal en un centro de referencia en Medellín-Colombia. Rev Colomb Gastroenterol. 2010;25(3):240-51.
Yepes-Barreto IJ, Carmona R, Díaz F, Marín-Jiménez I. Prevalencia y características demográficas de la enfermedad inflamatoria intestinal en Cartagena, Colombia. Rev Colomb Gastroenterol. 2010;25(2):107-11.
Silverberg M, Satsangi J, Ahmad T. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5-36.
https://doi.org/10.1155/2005/269076
Best W, Becktel J, Singleton J, Kern F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70(3):439-44.
https://doi.org/10.1016/S0016-5085(76)80163-1
Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956-63. https://doi.org/10.1016/0016-5085(90)90613-6
Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, Villanacci V, Becheanu G, Borralho Nunes P, Cathomas G, Fries W, Jouret-Mourin A, Mescoli C, de Petris G, Rubio CA, Shepherd NA, Vieth M, Eliakim R; European Society of Pathology (ESP); European Crohn’s and Colitis Organisation (ECCO). European consensus on the histopathology of inflammatory bowel disease.
J Crohn’s Colitis. 2013;7(10):827-51.
https://doi.org/10.1016/j.crohns.2013.06.001
Reyes GA, Gil FL, Carvajal GD, Sánchez CB, Aponte DM, González CA, Gamba JI, Preciado JA, Marulanda JC, Sabbagh LC. Enfermedad inflamatoria intestinal: características de fenotipo y tratamiento en un hospital universitario de Bogotá. Rev Col Gastroenterol. 2018;117-26. https://doi.org/10.22516/25007440.196
Höie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, Odes S, Mouzas IA, Beltrami M, Langholz E, Stockbrügger R, Vatn M, Moum B; European Collaborative Study Group of Inflammatory Bowel Disease (EC-IBD). Ulcerative colitis: Patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007;102(8):1692-701. https://doi.org/10.1111/j.1572-0241.2007.01265.x
Wolters FL, Russel MG, Sijbrandij J, Ambergen T, Odes S,
Riis L, Langholz E, Politi P, Qasim A, Koutroubakis I, Tsianos E, Vermeire S, Freitas J, van Zeijl G, Hoie O, Bernklev T, Beltrami M, Rodriguez D, Stockbrügger RW, Moum B. Phenotype at diagnosis predicts recurrence rates in Crohn’s disease. Gut. 2006;55(8):1124-30.
https://doi.org/10.1136/gut.2005.084061
Argüello M, Archila P, Sierra F, Otero W. Enfermedad inflamatoria intestinal. Rev Col Gastroentol. 1991;6(4):237-72.
Ka-Ho L, Hiu-Gong H, Chi-Ho N. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: Experience from a single center in Hong Kong. J Gastroenterol Hepatol. 2008;23(3):406-10.
https://doi.org/10.1111/j.1440-1746.2007.05079.x
Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over year. Gastroenterology. 1994;107(1):3-11.
https://doi.org/10.1016/0016-5085(94)90054-x
Larion S, Tavakoli H, Dececchis D, Arnold J, Vanslyke J. Psychiatric comorbidities in inflammatory bowel disease. Curr Psychiatry Rev. 2015;11(2):124-9.
https://doi.org/10.2174/157340051102150502083333
Goodhand JR, Wahed M, Mawdsley JE, Farmer AD, Aziz Q, Rampton DS. Mood disorders in inflammatory bowel disease: Relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis. 2012;18(12):2301-9.
https://doi.org/10.1002/ibd.22916
Trier Moller F, Andersen V, Andersson M, Jess T. Hospital admissions, biological therapy, and surgery in familial and sporadic cases of inflammatory bowel disease: A population-based cohort study 1977-2011. Inflamm Bowel Dis. 2015;21(12):2825-32.
https://doi.org/10.1097/MIB.0000000000000545
Childers RE, Eluri S, Vazquez C, Weise RM, Bayless TM, Hutfless S. Family history of inflammatory bowel disease among patients with ulcerative colitis: A systematic review and meta-analysis. J Crohn’s Colitis. 2014;8(11):1480-97. https://doi.org/10.1016/j.crohns.2014.05.008
Ng S, Tang W, Ching J. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145(1):158-65.
https://doi.org/10.1053/j.gastro.2013.04.007
Lakatos L, Kiss LS, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Lakatos PL. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis. 2011;17(12):2558-65. https://doi.org/10.1002/ibd.21607
Nuij V, Zelinkova Z, Rijk M. Phenotype of inflammatory Netherlands: Bowel disease at diagnosis in the Delta, a population-based inception cohort study (the Delta Cohort). Inflamm Bowel Dis. 2013;19(10):2215-22. https://doi.org/10.1097/MIB.0b013e3182961626
Cantoro L, Di Sabatino A, Papi C, Margagnoni G, Ardizzone S, Giuffrida P, Giannarelli D, Massari A, Monterubbianesi R, Lenti MV, Corazza GR, Kohn A. The time course of diagnostic delay in inflammatory bowel disease over the last sixty years: An Italian multicentre study. J Crohns Colitis. 2017;11(8):975-80.
https://doi.org/10.1093/ecco-jcc/jjx041
Lee DW, Koo JS, Choe JW, Suh SJ, Kim SY, Hyun JJ, Jung SW, Jung YK, Yim HJ, Lee SW. Diagnostic delay in inflammatory bowel disease increases the risk of intestinal surgery. World J Gastroenterol. 2017;23(35):6474-81. https://doi.org/10.3748/wjg.v23.i35.6474
Mitsuyama K, Niwa M, Takedatsu H, Yamasaki H, Kuwaki K, Yoshioka S, Yamauchi R, Fukunaga S, Torimura T. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1304-10. https://doi.org/10.3748/wjg.v22.i3.1304
Svoboda Baldin RK, Telles JEQ, Bonardi RA, Amarante HMB dos S, Júnior AB. Do standardization and quantification of histopathological criteria improve the diagnosis of inflammatory bowel disease? J Bras Patol e Med Lab. 2014;50(3):221-8.
https://doi.org/10.5935/1676-2444.20140019
Shi HY. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2018;47(3):364-70.
https://doi.org/10.1111/apt.14430
Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselink-van de Kruijs MA, Cilissen M, Engels LG, Van Deursen C, Hameeteman WH, Wolters FL, Russel MG, Stockbrügger RW. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009;104(2):371-83. https://doi.org/10.1038/ajg.2008.38
Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, Bernklev T, Henriksen M, Sauar J, Vatn MH, Moum B; IBSEN Study Group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431-40.
https://doi.org/10.1080/00365520802600961
Bailey EH, Glasgow SC. Challenges in the medical and surgical management of chronic inflammatory bowel disease. Surg Clin North Am. 2015;95(6):1233-44.
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
